00:00

1X

By: Jon Harol, Founder, Lighthouse Lab Services

The clinical laboratory industry may be on the verge of one of its largest growth opportunities in decades.

The catalyst is the emergence of Multi-Cancer Early Detection (MCED) testing, blood-based screening assays capable of detecting signals associated with multiple cancers simultaneously, often before symptoms appear. Combined with the momentum created by the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, MCED testing has the potential to reshape preventive medicine, create entirely new diagnostic workflows, and inject billions of dollars of new reimbursement revenue into the laboratory ecosystem.

For clinical laboratories, this is not simply a new test category. It may represent the beginning of a new era in population-scale cancer screening.

A New Reimbursable Screening Category

Historically, cancer screening has been fragmented and cancer-specific:

• Mammograms for breast cancer
• Colonoscopies for colorectal cancer
• Low-dose CT scans for lung cancer

MCED changes that model by introducing the possibility of detecting multiple cancers from a single blood draw.

The MCED legislation creates a pathway for Medicare reimbursement of FDA-approved MCED tests beginning in 2028. Importantly, this legislation establishes:

• A formal Medicare benefit category
• National coverage potential through CMS
• A reimbursement framework tied to preventive screening

This is significant because reimbursement drives adoption in healthcare. Once Medicare creates a viable reimbursement pathway, providers, health systems, laboratories, and investors begin building infrastructure around the opportunity.

Why This Matters to Clinical Laboratories

The clinical diagnostic laboratory industry has spent years navigating reimbursement pressure, staffing shortages, and consolidation. MCED testing could provide an entirely new source of growth.

Massive Testing Volume Potential:

Medicare covers tens of millions of Americans, many of whom fall into the highest-risk age groups for cancer. Even conservative adoption assumptions create enormous testing volume opportunities. For example:

• 100 laboratories
• 2,000 MCED tests annually per lab
• = 200,000 tests per year

At premium reimbursement rates associated with advanced molecular diagnostics, this quickly becomes a meaningful revenue stream for laboratories.

Unlike episodic molecular testing, MCED screening also has the potential to become:

• Annual
• Preventive
• Population-based

That creates recurring testing demand on a national scale.

A New Revenue Stream for Independent Labs:

One of the most important aspects of MCED is that it may allow independent and regional laboratories to participate in high-value molecular diagnostics without competing directly against traditional centralized mega-labs. If distributed deployment models emerge, independent labs could:

• Offer MCED testing locally
• Participate in revenue-sharing arrangements
• Expand molecular capabilities
• Strengthen physician relationships

This could provide a much-needed economic lift to many laboratories that have struggled with declining reimbursement in routine testing categories.

Increased Demand for Advanced Lab Infrastructure:

MCED testing is highly sophisticated and typically involves:

• Liquid biopsy workflows
• Genomic sequencing
• Cell-free DNA analysis
• Advanced bioinformatics

As adoption grows, laboratories will likely invest heavily in:

• Molecular instrumentation
• Automation
• Quality systems
• Data analytics
• Laboratory-developed workflow optimization

This infrastructure investment could create a broader modernization wave across the laboratory industry.

Medicare Could Be Just the Beginning

The real long-term opportunity may extend far beyond Medicare. Historically, commercial insurance companies often follow Medicare’s lead, particularly when:

• Clinical utility is demonstrated
• Outcomes improve
• Long-term healthcare costs decline

If MCED testing demonstrates:

• Earlier cancer detection
• Reduced late-stage treatment costs
• Improved survival outcomes
• Better population health metrics

Commercial payors will face increasing pressure to provide coverage as well.

Why Commercial Insurance Adoption Could Accelerate Rapidly

Cancer treatment is extraordinarily expensive, especially in later stages. If MCED testing helps identify cancers earlier, payors could potentially reduce:

• Hospitalizations
• Advanced oncology treatment costs
• Long-term care expenses
• Catastrophic claims exposure

From a health economics perspective, earlier intervention often costs significantly less than treating advanced disease. As clinical evidence accumulates, commercial insurers may increasingly view MCED testing not as an added expense, but as a cost-containment strategy. That transition could dramatically expand the addressable market beyond Medicare beneficiaries into:

• Employer-sponsored health plans
• Medicare Advantage
• ACA exchange plans
• Self-funded employer groups

A Shift Toward Preventive Diagnostics

MCED also represents a philosophical shift in healthcare. For decades, diagnostics have primarily been reactive:

• Symptoms appear
• Testing is ordered
• Disease is diagnosed

MCED moves diagnostics upstream into proactive population screening. This aligns with broader healthcare trends toward:

• Preventive medicine
• Value-based care
• Risk stratification
• Longitudinal patient monitoring

Clinical laboratories are uniquely positioned to become central infrastructure providers in this transition.

The Competitive Landscape Will Change

As the market develops, laboratories that move early may gain significant advantages:

• Established physician adoption
• Operational experience
• Reimbursement expertise
• Integrated workflows
• Strategic partnerships with MCED developers

The laboratories and service providers that build infrastructure before widespread reimbursement adoption may ultimately define the market.

Challenges Still Exist

Despite the excitement, several hurdles remain:

• FDA approval timelines
• CMS coverage decisions
• Clinical utility validation
• Provider education
• False positive management
• Workflow integration

However, the trajectory is clear: healthcare is moving toward earlier, blood-based cancer detection. The combination of:

• Medicare reimbursement
• Advancing liquid biopsy technology
• Growing clinical evidence
• Commercial payor interest

creates one of the most important growth opportunities the laboratory industry has seen in years.

Bottom Line

Multi-Cancer Early Detection testing has the potential to:

• Create a new reimbursed diagnostic category
• Drive significant new revenue into clinical laboratories
• Accelerate molecular lab expansion
• Increase demand for advanced diagnostics infrastructure
• Shift healthcare toward proactive cancer detection

And if commercial insurance companies ultimately follow Medicare’s lead, the long-term impact on the laboratory industry could be profound. For laboratories, healthcare systems, and diagnostic innovators alike, MCED may become one of the defining healthcare market shifts of the next decade.

Interested in learning more about this emerging line of testing and whether it would be a good fit for your lab and patient population? Contact us today to schedule a complimentary consultation.

Sharing is caring!